The vaccine manufacturer Biontech again made billions in profits last year and now wants to further advance the development of therapies, for example against cancer, in view of the declining revenues from the corona vaccine. In 2022, the Mainz-based company's revenues totaled 17.3 billion euros after almost 19 billion in the previous year, as the company announced on Monday. The bottom line is that Biontech posted a net profit of 9.4 billion euros and thus also slightly less than 2021 with 10.3 billion. For 2023, the company expects sales of around 5 billion euros with Covid-19 vaccines.

In 2021, Biontech and US partner Pfizer had delivered more than 2.6 billion doses of corona vaccines, last year only around 2 billion doses were invoiced. In addition to corona vaccines, Biontech is also researching approaches in immunotherapy based on the messenger molecule mRNA in the fight against infectious and autoimmune diseases as well as cancer. For future oncology products, the Mainz-based company would like to set up a sales organization in the USA, the EU and other selected regions this year and next.

Overall, the company is planning investments in research and development of 2.4 to 2.6 billion euros in 2023. Another part of the billions in profit is to flow into another share buyback program. The company's management would like to have a corresponding program approved in the amount of up to 0.5 billion euros for the period up to the end of 2023.